Rose McNulty

The class of diabetes drug has a protective effect on the kidneys for reasons beyond glucose control.

Funding cuts for research intended to make treatment and cures available and accessible for patients with HIV could affect HIV care in the long term.

Empathy and communication strengthen patient-provider relationships and improve respiratory care outcomes, as discussed at the European Respiratory Society (ERS) Congress.

David Rometo, MD, weighs various weight loss treatments, their success, and sustainability.

New treatment options are needed for patients with accelerated-phase or blast-phase myeloproliferative neoplasms (MPNs) ineligible for standard care.

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment.

David Rometo, MD, of UPMC, addresses stigma surrounding obesity and group setting weight loss intervention therapies and how consults benefit patients.

Weight loss medications show promise in improving liver health for those with chronic liver conditions, a review found.

Aumolertinib was compared against osimertinib to demonstrate its efficacy in those with mutated non-small cell lung cancer (NSCLC).

Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

Adverse events related to the immune system tended to accumulate over time when patients used immune checkpoint inhibitors (ICIs) over time.

Although overall costs have not declined with the Oncology Care Model (OCM), supportive care costs have decreased through greater use of cost-effective therapies.

An eHealth survey revealed widespread confusion, low awareness of 2026 Medicare plan changes, and growing interest in artificial intelligence support.

Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care.

UC Davis pharmacy residents research medication management and patient care, focusing on how pharmacists improve outcomes and reduce readmissions, according to Jeremiah J. Duby, PharmD, BCPS, BCCCP.

The Trump administration advances the Most Favored Nation order by partnering with Pfizer, which came to the table voluntarily and has been granted a reprieve from upcoming drug tariffs.

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

A wearable cough monitor generated clinically useful cough data, but patients only wore the device about half of the days of the study period.

The approval of remibrutinib for patients with chronic spontaneous urticaria was supported by data from the phase 3 REMIX-1 and REMIX-2 clinical trials.

Patients with immunoglobulin M-type monoclonal gammopathy did not experience a survival benefit from targeted therapies, a study found.

Paternal prepubertal passive smoke exposure is linked to impaired lung function trajectories in offspring, persisting into adulthood.

Second primary malignancies in patients with small cell lung cancer are often misdiagnosed as distant metastases.

Electronic health record (EHR)–based “e-phenotypes” combining lab data, coding, and AI could dramatically improve early detection and management of chronic kidney disease.

Emma Guttman-Yassky, MD, PhD, discusses the long-term efficacy of deuruxolitinib in alopecia areata.

Research exploring protective mechanical ventilation strategies for acute respiratory distress syndrome was presented at the ERS Congress by Luca Menga, MD, University of Toronto.

Guselkumab becomes the first interleukin-23 inhibitor approved for children with plaque psoriasis or active psoriatic arthritis.

Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.

Atezolizumab or durvalumab, combined with platinum-doublet regimens, delivered superior responses and survival in patients often excluded from clinical trials.

High-risk patients who cannot find a matched sibling or matched unrelated donor may achieve a similar benefit from a haploidentical donor.

Oral upadacitinib combined with topical ruxolitinib cream may be a promising therapeutic approach for patients with progressive nonsegmental vitiligo.